S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Tech insider: "Watch your mailbox" (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Tech insider: "Watch your mailbox" (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Tech insider: "Watch your mailbox" (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Tech insider: "Watch your mailbox" (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:TNYA

Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

$5.22
-0.08 (-1.51%)
(As of 02/23/2024 ET)
Today's Range
$5.07
$5.32
50-Day Range
$2.09
$6.32
52-Week Range
$1.66
$8.09
Volume
315,937 shs
Average Volume
570,379 shs
Market Capitalization
$355.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.80

Tenaya Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
202.7% Upside
$15.80 Price Target
Short Interest
Bearish
5.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Tenaya Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.69) to ($1.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

447th out of 943 stocks

Biological Products, Except Diagnostic Industry

68th out of 153 stocks


TNYA stock logo

About Tenaya Therapeutics Stock (NASDAQ:TNYA)

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

TNYA Stock Price History

TNYA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TNYA Mar 2024 7.500 put
TNYA Apr 2024 7.500 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Tenaya Announces Pricing Of $50 Mln Underwritten Offering; Stock Up
DBX, CMPS and EWBC are among after hour movers
Tenaya Therapeutics Inc TNYA
See More Headlines
Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/24/2024
Next Earnings (Estimated)
3/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TNYA
Fax
N/A
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.80
High Stock Price Target
$23.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+202.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-123,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.64 per share

Miscellaneous

Free Float
45,069,000
Market Cap
$355.54 million
Optionable
Optionable
Beta
2.50
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Faraz Ali M.B.A. (Age 51)
    CEO, Secretary & Director
    Comp: $816.39k
  • Dr. Deepak Srivastava M.D. (Age 58)
    Scientific Founder, Chairman of Scientific Advisory Board & Director
    Comp: $118k
  • Dr. Timothy Hoey Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $573k
  • Dr. Whittemore G. Tingley M.D. (Age 56)
    PH.D., Chief Medical Officer
    Comp: $621.98k
  • Dr. Eric N. Olson Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Dr. Bruce R. Conklin
    Scientific Founder
  • Dr. Saptarsi Haldar M.D.
    Scientific Founder
  • Dr. Sheng Ding Ph.D.
    Scientific Founder
  • Dr. Benoit G. Bruneau Ph.D.
    Scientific Founder
  • Ms. Leone D. Patterson M.B.A. (Age 61)
    Chief Financial & Business Officer
    Comp: $448.55k














TNYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenaya Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNYA shares.
View TNYA analyst ratings
or view top-rated stocks.

What is Tenaya Therapeutics' stock price target for 2024?

7 brokers have issued 12 month target prices for Tenaya Therapeutics' stock. Their TNYA share price targets range from $7.00 to $23.00. On average, they anticipate the company's stock price to reach $15.80 in the next year. This suggests a possible upside of 202.7% from the stock's current price.
View analysts price targets for TNYA
or view top-rated stocks among Wall Street analysts.

How have TNYA shares performed in 2024?

Tenaya Therapeutics' stock was trading at $3.24 at the beginning of the year. Since then, TNYA stock has increased by 61.1% and is now trading at $5.22.
View the best growth stocks for 2024 here
.

Are investors shorting Tenaya Therapeutics?

Tenaya Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 2,680,000 shares, an increase of 14.0% from the January 15th total of 2,350,000 shares. Based on an average daily trading volume, of 453,600 shares, the days-to-cover ratio is presently 5.9 days. Approximately 6.0% of the company's stock are sold short.
View Tenaya Therapeutics' Short Interest
.

When is Tenaya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our TNYA earnings forecast
.

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.20.

When did Tenaya Therapeutics IPO?

(TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Who are Tenaya Therapeutics' major shareholders?

Tenaya Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.67%), Price T Rowe Associates Inc. MD (6.67%), Vanguard Group Inc. (3.61%), GSA Capital Partners LLP (0.69%), Northern Trust Corp (0.57%) and Bridgeway Capital Management LLC (0.28%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Faraz Ali, Group Gp Lp Column III and Timothy Hoey.
View institutional ownership trends
.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNYA) was last updated on 2/25/2024 by MarketBeat.com Staff